Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2021 - 2023)

Insight Molecular Diagnostics' Liabilities from Discontinued Operations history spans 3 years, with the latest figure at 45000.0 for Q4 2023.

  • On a quarterly basis, Liabilities from Discontinued Operations fell 97.76% to 45000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 45000.0, a 97.76% decrease, with the full-year FY2023 number at 45000.0, down 97.76% from a year prior.
  • Liabilities from Discontinued Operations hit 45000.0 in Q4 2023 for Insight Molecular Diagnostics, down from 90000.0 in the prior quarter.
  • Over the last five years, Liabilities from Discontinued Operations for IMDX hit a ceiling of 2005000.0 in Q4 2022 and a floor of 45000.0 in Q4 2023.
  • Historically, Liabilities from Discontinued Operations has averaged 672833.33 across 3 years, with a median of 185500.0 in 2023.
  • Biggest five-year swings in Liabilities from Discontinued Operations: surged 31.39% in 2022 and later tumbled 97.76% in 2023.
  • Tracing IMDX's Liabilities from Discontinued Operations over 3 years: stood at 1526000.0 in 2021, then surged by 31.39% to 2005000.0 in 2022, then tumbled by 97.76% to 45000.0 in 2023.
  • Business Quant data shows Liabilities from Discontinued Operations for IMDX at 45000.0 in Q4 2023, 90000.0 in Q3 2023, and 135000.0 in Q2 2023.